• Empower (CBDT) has closed a C$2.1M private placement of unsecured convertible debenture units
  • The debentures bear interest at 6 per cent per annum, mature on March 25, 2024, and are convertible at $0.20 per share prior to maturity
  • The company intends to use the proceeds for working capital, general administrative expenses and to advance its growth plans
  • Empower Clinics is an integrated health care company
  • Empower (CBDT) is unchanged trading at $0.22 per share

Empower (CBDT) has closed a C$2.1M private placement.

The company sold units consisting of one senior unsecured convertible debenture priced at $1,000 and 5,000 common share purchase warrants.

Each warrant is exercisable into one Empower common share priced at $0.30 until March 25, 2024.

The debentures bear interest at 6 per cent per annum and mature on March 25, 2024.

At the option of the holder, the debentures are convertible into shares at any time prior to maturity at a conversion price of $0.20 per share.

The company intends to use the proceeds for working capital, general administrative expenses and to advance its growth plans.

“Our company, our path and the health care foundation we are building is in great shape,” stated Steven McAuley, Empower’s Chair and CEO. “We have evolved through these changing times, and we embrace our change. We embark, with legacy assets departed, and an abundance of opportunities in our journey ahead.”

Empower Clinics is an integrated health care company offering clinical services, digital and telemedicine care, medical devices and medical diagnostics.

Empower (CBDT) is unchanged trading at $0.22 per share as of 9:41 am EST.

More From The Market Online

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.